848482-93-9

Basic information

• Product Name: (S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID
• Synonyms: (S)-PIPERAZINE-1,3-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER;(S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID;(S)-4-(TERT-BUTOXYCARBONYL)PIPERAZINE-2-CARBOXYLIC ACID;4-BOC-PIPERAZINE-2-(S)-CARBOXYLIC ACID;(S)-1-Boc-piperazine-3-carboxylic acid;S-4-N-BOC-2-CARBOXYLIC ACID PIPERAZINE;S-4-N-BOC-2-PIPERIDINE CARBOXYLIC ACID;(S)-1-N-Boc-piperazine-3-carboxylic acid
• CAS NO: 848482-93-9
• Molecular Formula: C₁₀H₁₈N₂O₄
• Molecular Weight: 230.26
• Product Categories: pharmacetical;Piperaizine
• Mol File: 848482-93-9.mol

Chemical Properties

• Melting Point: 231-239 ºC
• Boiling Point: 371.8 °C at 760 mmHg
• Flash Point: 178.6 °C
• Appearance: /
• Density: 1.193 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 2.20±0.20(Predicted)
• CAS DataBase Reference: (S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID(848482-93-9)
• EPA Substance Registry System: (S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID(848482-93-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36-43
• Safety Statements: 26-36/37
• Hazardous Substances Data: 848482-93-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID serves as a key intermediate in the synthesis of various pharmaceuticals. Its role is pivotal for the development of new drugs, given its ability to be further functionalized and incorporated into complex molecular structures. The Boc protecting group ensures the stability of the compound during the synthesis process, allowing for the creation of a diverse range of therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, (S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID is utilized as an intermediate in the production of pesticides and other agrochemicals. Its chemical properties make it suitable for the development of compounds that can effectively manage pests and diseases in agriculture, thereby contributing to increased crop yields and food security.
Used as a Building Block in Organic Synthesis:
(S)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID is employed as a fundamental building block in organic synthesis, enabling the construction of a wide array of chemical compounds. Its versatility and the presence of the Boc protecting group make it an attractive candidate for the synthesis of various organic molecules, including those with potential applications in materials science, medicinal chemistry, and other specialized fields.

Upstream product

• 98-96-4 pyrazinamide 
• 1192014-44-0 C₈H₁₂N₂O₃ 
• 147650-70-2 (2S)-piperazine-2-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 73371-96-7 2-<<(tert-butoxycarbonyl)oxy>imino>-2-phenylacetonitrile 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 

Downstream Products

• 150407-69-5 [2S]-1-benzyloxycarbonyl-4-t-butoxycarbonylpiperazine-2-carboxylic acid 
• 244132-27-2 (S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid 
• 1256387-23-1 (S,S,S,S)-(1-(2-(5-(4-(4-(2-(1-(2-methoxycarbonylamino-3-methylbutyryl)-4-(2,2,2-trifluoroethyl)piperazin-2-yl)-1H-imidazol-4-yl)phenylethynyl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carbonyl)-2-methylpropyl)carbamic acid methyl ester 
• 314741-38-3 1-benzyl 4-(tert-butyl) 2-methyl (2S)-piperazine-1,2,4-tricarboxylate 
• 1462904-46-6 C₁₄H₁₈N₂O₄*C₂HF₃O₂ 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF A CHIRAL PIPERAZINE-2-CARBOXYLIC ACID

The invention relates to a novel process for the preparation of a chiral piperazine-2- carboxylic acid or of a salt thereof of the formula (I). The chiral piperazine-2-carboxylic acid derivatives of the formula (I) are key intermediates for the preparation of fused heteroaryl dihydro pyrimidines which are useful for the treatment and prophylaxis of hepatitis B virus infections.

RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF

The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.

A traceless, solid-supported synthesis ofβ-turn mimetics based on the hexahydropyrazino[1,2-α ]pyrazine-1,2-dione scaffold

The solid-supported synthesis of a library of-turn mimetics based on the three-component Petasis condensation and 2,5-diketopiperazine formation is reported. The eight-step sequence starts from optically pure (S)-piperazine-2-carboxylic acid dihydrochloride, which is first converted into an orthogonally protected, resin-bound amino derivative. The subsequent transformations lead to compounds having the common hexahydropyrazino[1,2-a] pyrazine-1,2-dione core and diverse side chains, which mimic the-turn structure. This synthetic route includes protection of the initial amino acid with two different protecting groups, followed by attachment to the Wang resin using the Mitsunobu reaction, deprotection of the-nitrogen atom, then Petasis reaction, amidation, deprotection of the-nitrogen atom, coupling with a Boc-protected-amino acid, cleavage of the Boc group, and the cyclizative cleavage from the resin, resulting in the requested bicyclic products obtained in good yields and having good to moderate purities. Six different boronic acids, four amines, and nine-amino acids were applied to this synthetic route, to explore the efficiency and limitations of the described method. Georg Thieme Verlag Stuttgart.

Disubstituted pyrimidines as Lck inhibitors

We have developed a family of 4-benzimidazolyl-N-piperazinethyl-pyrimidin-2-amines that are subnanomolar inhibitors of Lck. A subset of these Lck inhibitors, with heterocyclic substituents at the benzimidazole C5, are also low-nanomolar inhibitors of cell

COMPOUNDS AND METHODS FOR TREATMENT OF HCV

Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination with additional antiviral agents, in a therapeutically effective amount.

L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor

A series of HIV protease inhibitors possessing a hydroxylaminepentanamide transition state isostere have been developed. Incorporation of a basic amine into the backbone of the L-685,434 (2) series provided antiviral potency combined with a highly improved pharmacokinetic profile in animal models. Guided by molecular modeling and an X-ray crystal structure of the inhibited enzyme complex, we were able to design L-735,524. This compound is potent and competitively inhibits HIV-1 PR and HIV-2 PR with K(i) values of 0.52 and 3.3 nM, respectively. It also stops the spread of the HIV-1(IIIb)-infected MT4 lymphoid cells at concentrations of 25-50 nM. To date, numerous HIV-PR inhibitors have been reported, but few have been studied in humans because they lack acceptable oral bioavailability. L-735,524 is orally bioavailable in three animals models, using clinically acceptable formulations, and is currently in phase II human clinical trials.